# Recipharm

Recipharm (founded 1995, Sweden) is investing multi-million sums in US sterile manufacturing, a new BFS line and high-potency OSD at Leganés, sharpening its access-enabling footprint.

Source: https://en.bioecon.ru/companies/recipharm/
Updated: 2026-06-24

- Country: Sweden

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | €827 million (2024) | https://firstwordpharma.com/story/5942160, https://www.recipharm.com/press-releases/recipharm-reports-record-2024-revenue-and-strategic-milestones |
| Headcount | over 5,000 employees | https://www.recipharm.com/press-releases/recipharm-reports-record-2024-revenue-and-strategic-milestones, https://www.recipharm.com/press-releases/recipharm-strengthens-high-potency-capabilities-new-pilot-and-development-investment |
| Production site | Global network includes facilities in France, Germany, India, Israel, Italy, Morocco, Portugal, Spain, Sweden, and the US | https://www.recipharm.com/press-releases/recipharm-reports-record-2024-revenue-and-strategic-milestones, https://www.recipharm.com/sites/recipharm-corp/files/recipharm/recourse/Recipharm-sterile-capabilities.pdf, https://www.recipharm.com/sites/recipharm-corp/files/recipharm/recourse/brochure/RecipharmFullServiceOffering_2026.pdf, https://www.recipharm.com/sites/recipharm-corp/files/recipharm/sustainability/sustainability-reports/Recipharm_Sustainability_report_2024.pdf |
| Funding | Multi-million dollar investments in US sterile manufacturing, new BFS line, and high-potency OSD capabilities at Leganés (2026) | https://www.recipharm.com/press-releases/recipharm-boosts-bfs-capacity-strategic-manufacturing-investment, https://www.recipharm.com/press-releases/recipharm-expands-us-sterile-fill-and-finish-capabilities-support-growing-demand-biologics-and-advanced-therapies, https://www.recipharm.com/press-releases/recipharm-strengthens-high-potency-capabilities-new-pilot-and-development-investment |
| Regulatory approval | Secured multiple FDA and global regulatory approvals (2024) | https://www.recipharm.com/press-releases/recipharm-reports-record-2024-revenue-and-strategic-milestones |
| Regulatory approval | Leganés site is FDA-approved and holds AEMPS, ANVISA, EMA, PMDA, and MFDS certifications | https://www.recipharm.com/about-us/locations/leganes |
| Capacity | Increased pre-filled syringes (PFS) and lyophilisation capacity across Europe and the US; Wasserburg site offers over 60 million PFS and vial capacity; added over 100 million ready-to-use sterile units in the US | https://www.recipharm.com/press-releases/recipharm-boosts-bfs-capacity-strategic-manufacturing-investment, https://www.recipharm.com/press-releases/recipharm-reports-record-2024-revenue-and-strategic-milestones |

Independent sources: firstwordpharma.com

## Technologies

- [Local manufacturing for market access](https://en.bioecon.ru/technology/local-manufacturing-for-market-access/)